TMPRSS2-ERG rearrangement, the most common ETS gene fusion in prostate cancer, brings ERG expression under androgen control via androgen receptor-mediated TMPRSS2 regulation and results in over-expression of ERG protein [3]. This evidence concerns the gene TMPRSS2 and prostate cancer.